Patient-Derived Organoids for Personalized Therapy in KRAS-Mutant Pancreatic Cancer

A preclinical study integrating patient-derived organoids and xenografts from 66 pancreatic cancer patient samples. The dataset includes results from next-generation sequencing of 425 oncogenes and in vitro screening with 32 drugs, validated in vivo. The work was authored by Xiaorui Wang and last updated in May 2026.

Use Cases

• Predicting patient-specific chemotherapy responses based on in vitro organoid drug screening results.
• Identifying synergistic drug combinations for KRAS-mutant cancers based on MEK/mTOR inhibitor testing.
• Benchmarking preclinical model fidelity by comparing organoid and xenograft drug response data.
• Training models to correlate genetic features from NGS data with drug sensitivity profiles.

Strengths

• Includes data from 66 patient samples with a 69% organoid and 31% xenograft establishment success rate.
• Features results from a 32-drug in vitro screening panel and validation of a synergistic drug combination.
• Demonstrates high consistency between in vitro organoid results and in vivo patient outcomes for a specific chemotherapy regimen.

Limitations

• Description metadata is limited; actual data quality requires manual inspection after download.
• Column-level documentation is absent; field semantics must be inferred after download.
• The study notes limitations including a small sample size and lack of tumor microenvironment components in the models.

Provenance

Source

figshare

Collection Method

Data was generated from a biobank of patient-derived organoids and xenografts, followed by next-generation sequencing and drug screening.

Freshness

Last updated 2026-05-15 04:21:47; freshness should be verified.